Cetuximab [cetuximab]
- Terms
-
Erbitux
-
C225
Erbitux
IMC C225
IMC-C225
MAb C225
A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors.
- DUI
- D000068818 MeSH Browser
- CUI
- M0422675
- History note
- 2016 (2000)
- Public note
- 2016; CETUXIMAB was indexed under ANTIBODIES, MONOCLONAL 2000-2013; and under ANTIBODIES, MONOCLONAL, HUMANIZED 2013-2015
Allowable subheadings
- AD
- administration & dosage 37
- AE
- adverse effects 23
- AN
- analysis
- BI
- biosynthesis
- BL
- blood
- CF
- cerebrospinal fluid
- CH
- chemistry 2
- CL
- classification
- DE
- drug effects 1
- EC
- economics 2
- GE
- genetics
- HI
- history
- IM
- immunology 1
- IP
- isolation & purification
- ME
- metabolism 1
- PK
- pharmacokinetics 1
- PD
- pharmacology 41
- PH
- physiology
- PO
- poisoning
- RE
- radiation effects
- TU
- therapeutic use 103
- TO
- toxicity 1
- UL
- ultrastructure
- UR
- urine
64Cu-DOTA-cetuximab Chemical MeSH Browser